Related Experiment Videos
Gene therapy for ovarian cancer (review)
Judith K Wolf1, A Dwayne Jenkins
1Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 440, Houston, TX 77030, USA. jwolf@mdanderson.org
Abstract:
The field of gene therapy presents exciting new opportunities for advances in the management of ovarian cancer. Clinical trials of gene therapy for ovarian cancer have explored the feasibility of delivering a variety of agents as well as highlighted problems with the delivery of therapeutic constructs. Major challenges include enhancing gene transfection with improved vectors, minimizing immunogenicity of viral vectors via novel molecular alterations, effecting tumor-selective gene delivery by targeting genetic alterations present only in tumor cells and utilizing tissue-specific promoters for selective transcription of gene products. Gene therapy research presents unique opportunities for extending the spectrum of ovarian cancer treatment possibilities, either alone or in combination with conventional chemotherapy regimens.
Insights
Gene therapy offers new ovarian cancer treatment options. Key challenges involve improving gene delivery, reducing immune responses, and targeting tumors specifically for better outcomes.
Area of Science:
- Oncology
- Genetics
- Biotechnology
Background:
- Ovarian cancer remains a significant health challenge with limited treatment advancements.
- Gene therapy presents a promising frontier for novel therapeutic strategies.
Purpose of the Study:
- To explore the potential of gene therapy in ovarian cancer management.
- To identify and address the challenges associated with current gene therapy approaches for ovarian cancer.
Main Methods:
- Review of clinical trials investigating gene therapy for ovarian cancer.
- Analysis of gene delivery vectors and their associated limitations.
- Examination of strategies to enhance gene transfection and minimize immunogenicity.
Main Results:
- Clinical trials have demonstrated the feasibility of gene therapy delivery in ovarian cancer.
- Significant challenges persist in vector efficiency, immunogenicity, and tumor-specific delivery.
- Targeting tumor-specific genetic alterations and using tissue-specific promoters are crucial for efficacy.
Conclusions:
- Gene therapy holds considerable promise for improving ovarian cancer treatment.
- Overcoming delivery and targeting challenges is essential for successful clinical application.
- Gene therapy can potentially be used as a standalone treatment or in conjunction with chemotherapy.